Objective Soluble HLAclass I antigens (sHLAs) in humanserum have been reported to be associated with allografts and autoimmune disease and could modify inimunological reactions induced by membranetype HLAs. To investigate the clinical significance of sHLAsin sarcoidosis, we assessed concentrations of sHLAsin both serum and bronchoalveolar lavage fluid (BALF) and also examined their production by peripheral blood mononuclear cells (PBMCs) and BALF cells. Methods Concentrations of sHLAswere determined by enzyme-linked immunosorbent assay, using a monoclonal antibody against HLAclass I (W6/32) and an enzyme-labeled polyclonal antibody to human (32-microglobulin.
Introduction
HLAclass I antigens, heterodimeric cell surface antigens composed of a 44 kDa highly polymorphic heavy chain and noncovalently associated 12 kDa (32 microglobulin (1), play an important role in the immunerecognition of antigens, response to organ transplants, and auto-immunedisease. Soluble HLAclass I antigens (sHLAs) found in normal human serum were first shown by Rood to inhibit anti-HLA sera (2) and modify the immunological reactions induced by membrane type HLA. Especially in liver transplantation, it has been reported that sHLAsreleased by liver parenchymal cells could induce tolerance against host rejection and monitoring of these antigens may be a useful indicator of graft pathology and function (3, 4) . Furthermore, elevation of sHLAshas been reported to be associated with some viral systemic infections, including cases with human immunodeficiency virus (5) and hepatitis virus (6) .
Sarcoidosis is a disease of unknownetiology characterized by the presence of noncaseating epithelioid cell granulomas in systemic organs, and several immunological disorders (7, 8) . Recent investigations into its pathogenesis have demonstrated that activated T cells at sites of inflammation are oligoclonal, consistent with a conventional antigen-driven T cell immune response (9-ll) . Considering the high serum levels of SHLA in association with an activated immuneresponse, we considered that these levels in patients with sarcoidosis might be of interest. In this study, we therefore examined whether sHLAs concentrations in sera and bronchoalveolar lavage fluid (B ALF) from patients maybe useful for the evaluation of disease activity. Wealso demonstrated that peripheral blood mononuclear cells (PBMCs) and BALFcells derived from active sarcoidosis patients release enhancedamountsof sHLAscomparedwith those from healthy controls.
Materials and Methods
Study population (Table 1) The serum of a total of 94 sarcoidosis patients, 37 menand 57 women with a mean (SD) age of 51.4±15.4 years, was evaluated for levels of sHLAs along with that from 32 individuals, 19 men and 13 womenwith a mean age of50.6±15.3 years, as normal subjects. Sarcoidosis was diagnosed based on the clinical picture and the presence of epithelioid cell granulomas in biopsy specimens from lung, skin, or lymph nodes (12) . According to the classification system defined by DeRemee (13) , there were 70 patients in roentgenographic stage I, 15 in stage II, and nine in stage III. Further, 53 patients were defined as having active disease since they had newly developed chest radiological abnormalities and clinical symptoms, or had a deterioration in chest radiographic findings and clinical status during the previous 3 months (14) . The others were considered to have inactive disease. None of the patients was receiving any corticosteroids. In this study population, 20 of patients with active sarcoidosis and 10 control subjects were examinedfor production of sHLAsfrom PBMCs. In 17 active sarcoidosis patients and 13 healthy control subjects, bronchoalveolar lavage (BAL) was performed as described previously (15) . Both serum and BALFwere stored at -30°C before being evaluated for the sHLAsconcentration.
All subjects had no history of cardiopulmonary or other medical illness including tuberculosis, infection, and autoimmunediseases. All the patients for which BALwas analyzed had normal pulmonary function tests and no history of smoking (Table 2) . Informed consent was obtained from each patient and normal volunteer under a protocol approved by the institutional review board.
Cell preparation and culture
Peripheral blood obtained from patients with active sarcoidosis and healthy donors was anticoagulated with heparin, and PBMCs were separated on a Ficoll-Hypaque (Pharmacia Biotech AB, Sweden) density gradient. To assess the production of sHLAsby cells, PBMCswere cultured in 1 ml of 2xlO6 endotoxin-tested RPMI 1640 (complete RPMI, Gibco BRL, Paisley, UK) supplemented with 100 U/ml penicillin, 100 |ig/ ml streptomycin, 2 mML-glutamine, HEPESbuffer and 10% heat-inactivated (56°C for 1 hour) FBS (ICN Row, Costa Mesa, CA, USA), and incubated with either lipopolysaccharide (LPS from Escherichea coli, serotype 0127: B8, Sigma Chemical Co., St. Louis, MO, USA) or phytohemagglutinin (PHA, Sigma Chemical Co.). After cells were incubated at 37°C in a waterjacketed 5%CO2 incubator for 24 to 72 hours, the cell free supernatant fluid was collected for determination of sHLAs c oncentration s.
BAL was performed using 150 ml of normal saline solution injected via a fiberoptic bronchoscope in 50 ml aliquots, with immediate vacuumaspiration after each aliquot. The fluid was filtered through sterile gauze and its volume measured. Lung cells were separated from BALFby centrifugation, washed three times in PBS, and then counted. Cell differential counts were carried out applying morphologic criteria to cytocentrifuged smears stained with Wright-Giemsa. Cell pellets were resuspended in complete RPMI 1640 containing 10% FCS and allowed to adhere to plastic culture dishes at 37°C in a waterjacketed 5% CO2 incubator. After 1 hour incubation, the cells were washed vigorously to remove non-adherent cells. Adherent cells were then removed from dishes by gentle scraping 
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with a rubber policeman. This procedure increased the proportion of cells morphologically compatible with alveolar macrophages (AMs). Following this multi-step selection procedure, more than 95%of the above cells were viable, as judged by trypan blue exclusion. Cells recovered from BALF(BALFcells) and AMswere resuspended at 5x lO5 cells/ml and after 24 hours of culture in the presence or absence of LPS or PHA, the production of sHLAswas examined.
Assay for sHLAs sHLAsprotein levels were measuredin samples using an enzyme-linked immunosorbent assay (ELISA) detection kit (Sang Stat Medical Co., Ltd., Menlo Park, CA, USA) according to the manufacturer's recommendations. This assay is a sandwich ELISAfor quantitation of soluble HLAantigen (HLA-A, B, C) with the procedure as follows: prepared standard (soluble HLA-B7)or diluted samples were added to wells of the microtiter plates coated with anti-humanmonomorphic class I monoclonal antibody (clone W6/32) in duplicate, and incubated for 90 minutes at room temperature. The plates were washed 3 times with PBS containing 0.05% Tween 20 (wash solution), followed by addition of horseradish peroxidase-conjugated rabbit anti-human P2-microglobulin polyclonal antibody into each well. After 60 minutes incubation at room temperature, the plates were washed 3 times with wash solution and finally, o-phenylene-diamine substrate solution was added and the plates were incubated at roomtemperature for 20 minutes in the dark. The color reaction was stopped with IN HC1 and the absorbance of each well was determined at 490 nm. A standard curve was prepared from four sHLAsstandards. The minimumvalue for detection was 3 ng/ml. A preliminary study showed serum levels of sHLAsin patients to be higher than in control subjects. Thus, the sera from patients were diluted 1: 50 with specimen diluents, while those from controls were diluted 1 :25. Culture supernatants were diluted 1/2. BALFwere concentrated 20 fold by MINICON-B(Amicon Division, W.R.Grace&Conn Co., Ltd., Beverly, MA, USA).
Serum angiotensin-converting enzyme(ACE) level measurement SerumACElevels were measured by a colorimetric method (Colorimetric assay kit, Fujizoki, Assay, Tokyo) using phydroxyhippuryl-L-leucine as the substrate ( 1 6).
Statistical analysis
Comparison of group data was accomplished using the unpaired two-tailed t test for data that were normally distributed. Data that were not normally distributed were comparedusing the nonparametric Mann-WhitneyU test. Linear regression analysis wasused to determine the correlation betweeninvestigated parameters. In all statistical evaluations, a p value of <0.05 was considered as significant.
Results sHLAslevels in serum and BALF
The value for serum sHLAsconcentration in the 94 patients with sarcoidosis was 2,501.8±1 ,921.2 ng/ml (meardzSD), which was significantly higher than that for 32 normal controls (l,230.9±791.6 ng/ml; p<0.05). Patients with active disease showed significantly increased levels of sHLAs as compared with those with inactive disease (3,961.9±1,677.0 and 843.8±715.0 ng/ml, respectively; p<0.001) ( Fig. 1) . Regarding the chest roentgenographic stage, we observed a tendency for increase in the order I<II<III, but there was no significant difference (data not shown). The results of BALFcells from both groups are summarized in Table 2 . The BALF cell count and differential were consistent with active sarcoidosis. As for the concentration in BALfluid, sHLAswere detectable in eight of 17 patients with sarcoidosis, but it was only detectable in one control. The level was higher in patients with sarcoidosis than in the control (p<0.05, using the nonparametric Mann-Whitney U test, Fig. 2 ). The concentration did not exhibit any statistical variation with the chest roentgenographic stage and did not correlate with either the percentage of lymphocytes or their CD4+/CD8+ratio. Because it has been shown that untreated patients with more active clinical sarcoidosis tend to have higher serum ACElevels (12, 17) , we next investigated the link with sHLAsin patients. As shown the Fig. 3 , there was a significantly positive correlation between serum levels of sHLAsand those of ACE (r=0.46, p<0.05).
sHLAslevels In supernatants of cultured PBMCs
To investigate the production of sHLAsby PBMCs,we measured the levels in culture supernatant (Fig. 4 ). After 24 hours of culture in mediumalone, cells from seven of 20 pa- LPS to the medium, PBMCsfrom patients generated higher amountsof sHLAscomparedwith those cultured in medium alone. In contrast, those from control subjects only generated limited low amounts, and solely in the presence of LPS for three days.
It has been shownthat in vitro stimulation of lymphocytes with a mitogen can induce sHLAssecretion (18) , and thus we examined the production of sHLAsby PBMCs upon exposure to PHA. An increase was observed with cells from both active sarcoidosis cases and control subjects, and there was no significant difference between the two groups ( 1 25.5±45.4 ng/ml and 108.8±16.7 ng/ml, respectively). sHLAslevels In supernatants of cultured BALFcells and AMs Regarding sHLAs generation by BALF cells, those from active sarcoidosis cases generated enhanced amounts of sHLAs compared with their counterparts from control subjects. As for the production of these antigens by AMs, the levels of sHLAs in active cases were also elevated. In both groups, however, production of sHLAsfrom both BALFcells and AMswas not affected by the presence or absence of either LPS or PHA (Fig.   5 ).
Sequential change of serum sHLAs In patients with active sarco idos is
When7 patients with active sarcoidosis were sequentially analyzed during the clinical course, sHLAslevels in serum fluctuated in conjunction with both serum levels of ACEand clinical status ( Table 3 ). Increase of sHLAslevels was observed with deterioration of the clinical picture, correlating with changes in ACE.
Discussion
Weconfirmed in the present study that both serum and BALF levels of sHLAsin patients with sarcoidosis are higher than those in control subjects. In sarcoidosis cases, serum concentrations with active disease were significantly higher than with inactive disease, correlating with ACElevels. To our knowledge, this is the first report demonstrating sHLAs in both serum and BALFfrom patients with sarcoidosis.
It has been documentedthat certain HLAphenotypes are associated with higher serum concentrations of sHLAs, and individuals with HLA-A23or HLA-A24have a higher value than those without these two antigens (19, 20) . However, our previous study of the association between HLAantigens and sarcoidosis in Japanese demonstrated the frequencies of these two antigens to be almost the same in both patients and control subjects (21) . It is therefore unlikely that a bias of HLAclass I alleles in the patients could explain the difference from the controls.
Wecannot explain the precise mechanisms of enhanced secretion of sHLAs by both PBMCsand BALFcells from patients with active sarcoidosis. Brieva et al (18) have shown that stimulated PBMCs from normal subjects actively secrete considerable amounts of sHLAs and that lymphocytes, including T cells and Bcells, are the main source in their culture condition. They demonstrated that PHAinduced a 20-fold mean increase of the secretion, thus it maybe possible that using PHA stimulation in our in vitro experiments did not give a precise evaluation for differential production of sHLAsbetween the two groups. Whereas they also demonstrated that both monocytes and neutrophils produced only background quantities of sHLAs by several stimulations, including LPS, our present data demonstrated that active sarcoid PBMCs produced them in enhanced amounts by stimulation of LPS compared with normalsubjects. Somestudies speculated that circulating sarcoid PBMCs might be involved in the disease. It has been reported that active sarcoid blood monocytesrelease increased levels of radical oxidants (22) and that sarcoid peripheral T lymphocytes express functional IL-2 receptors (23) . It has also been demonstrated that PBMCs from active patients express relatively low levels of interleukin (IL) 10, which is thought to inhibit activation of cellular immuneresponses, compared with healthy subjects (24) . Thus our present in vitro data regarding the production form PBMCs may reflect an immunologically activated status observed in these cells from patients with active sarcoidosis.
Enhanced production of sHLAsfrom both BALFcells and AMs in active sarcoid patients could be related also to the immunological activation of the lungs observed in this disease. It has been reported that AMsfrom active disease sites have several immunereactivities including enhanced IFN-gammaproduction, inducing immunological features associated with ac- CD4+CD45RO+ T cells at sites of disease proliferate at exaggerated rate and release IL-2 and other cytokines (8-1 1). Thus further investigations, including immunohistochemical examination of biopsy specimens from patients are needed to clarify the relationship between the activated immunological status of disease sites and the production of sHLAsin sarcoidosis. The reason why production of sHLAsby both BALFcells and AMs was not affected by in vitro stimulation might be associated with immunological differences of these cells from PBMCs. The lung has the specific immunological status where mucosaltissues are continuously exposed to an abundanceof antigens and it has been reported that AMsfrom healthy subjects are paradoxically ineffective in presenting antigen to T cells (28) .
The serum level of sHLAs is high in diseases in which lymphocyte activation plays a pivotal role in disease pathogenesis, and is thought to reflect immune reactivity in host (29) . An increase in serum level of sHLAswas found in patients with active SLE (30), HIV infection (5) , and chronic hepatitis (6) and monitoring of these antigens is thought to be a useful indicator of activity of these diseases. In other granulomatous lung diseases, it is also reported that active tuberculosis patients were shown to have increased levels of sHLAsin serum (31) . We observed that serum levels of sHLAsin patients with sarcoidosis were correlated with those of ACEand fluctuated in conjunction with clinical manifestation. Considering that sarcoidosis is a disease characterized by formation of granulomas, accompanied by systemic immunological features of ongoing activation discussed above, elevation of serum levels of sHLAs maybe related to the immunereactivity in this disease and thus measurement of these levels in patients could be useful as a marker of disease activity.
It has been demonstrated that there are at least three forms of sHLAs (32) associated with p2-microglobulin in human.
The 44 kDa class I heavy chain is considered to be derived by membrane shedding, the 39 kDa heavy chain which lacks the transmembrane domain is generated by alternative splicing, and the 37 or 35 kDa heavy chains are thought to represent products from proteolysis of the intact 44 kDa heavy chain. The assay used in this study detects all forms of heavy chains associated with p2-microglobulin, and it is unclear whether any one form of sHLAsis selectively increased in patients with sarcoidosis. In our further studies, it would be of interest to differentially quantitate the serum concentrations of the various forms of sHLAs. The elevation of serum levels of sHLAsmay be related to immune reactivity in the host, while the biological significance and function of sHLAsremains unclear. In regard to the biological significance of sHLAs, particularly after allogenic organ transplantation, Zavazava et al demonstrated that sHLAs inhibit activated T lymphocytes by inducing apoptosis in allospecific fashion (33) . The same group has also reported that a high and stable serum concentration of sHLAsof donor origin characterized longterm stable allograft function in cases of liver transplantation (34) . Further investigations are needed to clarify the biological significance of sHLAsin the patho-genesis in sarcoidosis.
